This study will evaluate the safety, pharmacokinetic profile and pharmacodynamic effects of the two Leuprolide Oral Tablet dosing regimens: Leuprolide Oral Tablet, 4 mg, administered QD for 28 consecutive days and Leuprolide Oral Tablet, 4 mg, administered BID for 28 consecutive days in comparison to leuprolide administered intramuscularly, Lupron Depot 3.75 mg.